^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

finasteride

Associations
Company:
Generic mfg.
Drug class:
Cholestenone 5-alpha reductase inhibitor
Associations
3d
5α-Reductase Isoenzymes: From Neurosteroid Biosynthesis to Neuropsychiatric Outcomes. (PubMed, NeuroSci)
Pharmacovigilance and clinical reports show that a subset of patients treated with finasteride or dutasteride may experience persistent psychiatric and sexual adverse effects, known as post-finasteride syndrome. The current findings underscore the need for careful patient counseling, systematic monitoring, and further translational studies integrating genetics, neuroendocrine markers, and standardized psychiatric outcomes to identify individuals at risk and advance personalized medicine in this field.
Review • Journal
|
SRD5A1 (Steroid 5 Alpha-Reductase 1) • SRD5A2 (Steroid 5 Alpha-Reductase 2)
|
finasteride
2ms
New P1 trial
|
finasteride
2ms
ZBTB7B modulates the androgen receptor as an upstream regulator via colocalization and direct binding in LNCaP prostate cancer cells. (PubMed, Transl Cancer Res)
Furthermore, AR inhibitor finasteride and AR activator dihydrotestosterone (DHT) did not affect ZBTB7B...Notably, N-terminal domain (NTD) of AR is requisite for binding with ZBTB7B in HEK293 cells, not AR-DNA-binding domain (DBD) or AR-ligand-binding domain (LBD) in HEK293 cells. Overall, these findings provide a novel insight that ZBTB7B promotes prostate cancer progression as a potent oncogene via colocalization and binding with AR.
Journal
|
AR (Androgen receptor) • CD8 (cluster of differentiation 8)
|
finasteride
2ms
GBP1 as a machine learning-prioritized biomarker and therapeutic target for epstein-barr virus-induced clear cell renal cell carcinoma: multi-omics causal validation. (PubMed, Int J Surg)
This work reveals a causal relationship between EBV infection and ccRCC pathogenesis, establishing GBP1 as a top-priority candidate molecule through a multi-level, multi-dimensional evidence framework. Drug prediction and molecular docking suggest finasteride as a potential inhibitor of GBP1, offering new strategies for the precise prevention and treatment of ccRCC.
Journal
|
GBP5 (Guanylate Binding Protein 5) • GBP1 (Guanylate Binding Protein 1) • IFI16 (Interferon Gamma Inducible Protein 16) • IL12RB1 (Interleukin 12 Receptor Subunit Beta 1) • RECQL (RecQ Like Helicase)
|
finasteride
3ms
BPH Management: New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia (clinicaltrials.gov)
P2, N=242, Recruiting, Beth Israel Deaconess Medical Center | Not yet recruiting --> Recruiting
Enrollment open
|
finasteride • raloxifene hydrochloride
3ms
Prostate cancer evolution after COVID-19-related prostatitis in a TMPRSS2-altered patient: a case report and review of the molecular interface between SARS-CoV-2 and prostate oncogenesis. (PubMed, Front Oncol)
Although symptoms improved with antibiotics, LUTS persisted and were managed with finasteride and doxazosin. This is the first documented case suggesting a potential link between COVID-19-related prostatitis and subsequent prostate cancer in a TMPRSS2::ERG-altered patient without hereditary predisposition. Although causality cannot be established, the findings highlight a hypothesis-generating interface between viral infection, inflammation, and oncogenesis that warrants further study.
Journal
|
PTEN (Phosphatase and tensin homolog) • ERG (ETS Transcription Factor ERG) • TMPRSS2 (Transmembrane serine protease 2)
|
finasteride
4ms
The therapeutic effect of i-PRF on androgenic alopecia and the expression of β-Catenin, CD34 and Ki67 in scalp tissue (ChiCTR2500107781)
P=N/A, N=100, Not yet recruiting, The Second Affiliated Hospital of Guangxi Medical University; The Second Affiliated Hospital of Guangxi Medical University
New trial
|
finasteride
4ms
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy (clinicaltrials.gov)
P=N/A, N=120, Recruiting, Beth Israel Deaconess Medical Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
Trial completion date • Trial primary completion date
|
finasteride
5ms
Androgen receptor signaling as a new target for intervention in acute myeloid leukemia. (PubMed, Blood Adv)
ARN509 and finasteride also showed pro-apoptotic effect in patient-derived AML cells and in a humanized AML model in NSG mice. These data support a drug repurpose effort to use anti-androgen therapy to improve the efficacy of AML treatments.
Journal
|
mTOR (Mechanistic target of rapamycin kinase) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • EPHA7 (EPH Receptor A7)
|
apalutamide • finasteride
6ms
Sleep Apnea in Elderly (clinicaltrials.gov)
P4, N=100, Recruiting, VA Office of Research and Development | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2025 --> Jul 2026
Trial completion date • Trial primary completion date
|
acetazolamide • finasteride
8ms
The postnatal offspring of finasteride-treated male rats show altered ERα and PCNA expression in the liver. (PubMed, Reprod Biol)
Additionally, the expression of ERα and PCNA was examined at the mRNA level. This paper is documenting that finasteride use by paternal generation males (in reproductive age) may lead to an intergenerational effect detrimental to the liver function of their male offspring.
Preclinical • Journal
|
ER (Estrogen receptor) • PCNA (Proliferating cell nuclear antigen)
|
finasteride